To investigate the prognostic significance of pretreatment inflammatory biomarkers in patients with advanced hypopharyngeal cancer（HPC） , 88 patients with Stage IV HPC treated with radiotherapy （RT） , chemoradiotherapy （CRT） , or bioradiotherapy （BRT） were enrolled and the impact of pretreatment inflammatory biomarkers including fibrinogen, the neutrophil-to-lymphocyte ratio （NLR）, the platelet-to-lymphocyte ratio （PLR） and the lymphocyte-to-monocyte ratio （LMR） on the survival of these patients was evaluated. These markers were categorized into two groups according to the results of receiver-operating characteristic plots for determining of the cut-off value. In the present study, NLR > _ 3.59 was associated with a poor overall survival （OS） and progression-free survival （PFS） in patients with advanced HPC. In addition, our multivariate analysis showed that an NLR > _ 3.59 was an independent prognostic factor for the OS and PFS. These results suggested that the NLR was a useful pretreatment biomarker for identifying advanced HPC patients likely to have a poor outcome.

